

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 April 2025 (03.04.2025)



(10) International Publication Number
WO 2025/068803 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/725 (2006.01)
A61K 31/00 (2006.01) C07K 16/30 (2006.01)
A61P 35/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2024/058587

(22) International Filing Date:

04 September 2024 (04.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/585,292 26 September 2023 (26.09.2023) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85,
Södertälje (SE).

(72) Inventors: **BOSCO, Emily**; c/o AstraZeneca Pharmaceu-
ticals LP, One MedImmune Way, Gaithersburg, Maryland
20878 (US). **ZANVIT, Peter**; c/o AstraZeneca Pharma-
ceuticals LP, One MedImmune Way, Gaithersburg, Mary-
land 20878 (US). **MCGLINCHEY, Kelly**; c/o AstraZeneca
Pharmaceuticals LP, One MedImmune Way, Gaithersburg,
Maryland 20878 (US). **PEZOLD, Jessica**; c/o AstraZeneca
Pharmaceuticals LP, One MedImmune Way, Gaithersburg,
Maryland 20878 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Eastbrook House, Shaftesbury Road, Cambridge Cam-
bridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: THERAPEUTIC COMBINATIONS COMPRISING ANTI-STEAP2 CHIMERIC ANTIGEN RECEPTOR T CELLS

(57) Abstract: The disclosure provides therapeutic combinations of chimeric antigen receptor T cells that specifically bind human STEAP2 (e.g., AZD0754) with androgen receptor antagonists (e.g., enzalutamide). Methods of administering the combinations to treat cancer (e.g., prostate cancer) are also provided.

WO 2025/068803 A1